Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110


Herbst R. S. , De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., ...Daha Fazla

SWISS MEDICAL WEEKLY, 2020 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası:
  • Basım Tarihi: 2020
  • Dergi Adı: SWISS MEDICAL WEEKLY